Clinical Profile of Thromboembolic Events in Patients With Hypertrophic Cardiomyopathy in a Regional Japanese Cohort　― Results From Kochi RYOMA Study ―

• Hirota Takayoshi

  Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University

• Kubo Toru

  Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University

• Baba Yuichi

  Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University

• Ochi Yuri

  Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University

• Takahashi Asa

  Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University

• Yamasaki Naohito

  Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University

• Hamashige Naohisa

  Department of Cardiology, Chikamori Hospital

• Yamamoto Katsuhito

  Department of Cardiology, Kochi Health Sciences Center

• Kondo Fumiaki

  Department of Cardiology, Japanese Red Cross Kochi Hospital

• Bando Kanji

  Department of Cardiology, Tosa Municipal Hospital

• Yamada Eisuke

  Department of Cardiology, Susaki Kuroshio Hospital

• Furuno Takashi

  Department of Cardiology, Kochi Prefectural Aki General Hospital

• Yabe Toshikazu

  Department of Cardiology, Kochi Prefectural Hata Kenmin Hospital

• Doi Yoshinori L.

  Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University Department of Cardiology, Chikamori Hospital

• Kitaoka Hiroaki

  Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University

Abstract

Background:There is limited information about the clinical profiles of patients with hypertrophic cardiomyopathy (HCM) and thromboembolic events in a community-based Japanese patient cohort. Methods and Results:In 2004, we established a cardiomyopathy registration network in Kochi Prefecture that comprised 9 hospitals, and finally 293 patients with HCM were followed. The mean age at registration was 63±14 years, and 197 patients (67%) were men. At registration, 86 patients (29%) had documented atrial fibrillation (AF). During a mean follow-up period of 6.1±3.2 years, thromboembolic events, including 3 embolic stroke deaths, occurred in 23 patients. The 5-year embolic event rate was 5.5%. During the follow-up period, an additional 31 patients (11%) had documentation of AF and finally a total of 117 patients (40%) developed AF. The 5-year embolic event rate in those 117 patients with AF was 12.3%. Of the 23 patients with embolic events, 12 had AF prior to the embolic complications and another 6 had documented AF after thromboembolism. AF was not detected in the remaining 5 patients. The CHADS₂score did not correlate with the embolic outcome in HCM patients. Conclusions:In this community-based registry, thromboembolic events were not rare in patients with HCM. All patients with HCM in whom AF develops should be given anticoagulation therapy regardless of their CHADS₂score.

Journal

• Circulation Journal

  Circulation Journal 83 (8), 1747-1754, 2019-07-25

  The Japanese Circulation Society

Keywords

• Atrial fibrillation
• CHADS₂ score
• Hypertrophic cardiomyopathy
• Thromboembolic events

Details

• CRID: 1390564238107837696
• NII Article ID: 130007683016
• NII Book ID: AA11591968
• DOI: 10.1253/circj.cj-19-0186
• ISSN: 13474820
• ISSN: 13469843
• NDL BIB ID: 029816926
• PubMed: 31257313
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I029816926
• Web Site: https://www.jstage.jst.go.jp/article/circj/83/8/83_CJ-19-0186/_pdf
• Text Lang: en
• Data Source:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed